Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees (the "Awardees"). The awards were approved by the Company's Compensation Committee, which is comprised of independent directors, on March 25, 2020 as an inducement material to the Awardees' entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).

The inducement grants to the Awardees consists of restricted stock unit ("RSU") awards. An aggregate of up to 14,400 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), are issuable upon settlement of the RSUs. The grant date for the RSUs was March 25, 2020. The issuance price of the RSUs is equal to the closing price per share of the Company's Common Stock, as reported by NASDAQ, on March 25, 2020.

One-third (33%) of the shares subject to the RSUs will vest on each anniversary of the grant date, subject to tenure requirements.

About Endologix

Endologix, Inc. develops, manufactures, markets and sells innovative medical devices for the treatment of aortic disorders. The Company's products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms ("AAA"). AAA occurs when a portion of the abdominal aorta bulges into an aneurysm because of a weakening of the vessel wall, which may result in life threatening internal bleeding upon rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it among the leading causes of death in the United States. For more information, visit www.endologix.com.